Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 11/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | RPS27 | P42677 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145009 | 0.86 | MAPK8 (0.60) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL1145819 | 0.85 | MAPK8 (0.48) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL1145775 | 0.83 | MAPK8 (0.49) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL31060517 | 0.78 | MAPK8 (1.00) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL1145050 | 0.78 | MAPK8 (1.00) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL1145692 | 0.77 | MAPK8 (0.57) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL15831629 | 0.74 | HPGD (0.59) | MAPK8MAPK9ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL1145445 | 0.73 | MAPK8 (0.60) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL13514556 | 0.72 | MAPK8 (0.54) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 | |
| SCHEMBL20606873 | 0.72 | MAPK8 (0.59) | MAPK8MAPK9PRKD3MAP4K4MAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | MAPK8 30/4885MAPK9 49/4885PRKD3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.